Zymosense is a leading nanotechnology firm specializing in enzyme activity measurement solutions. The company's groundbreaking mobile "mix and read" assay technology offers a simple, fast, and reliable method for enzyme analysis, driving innovation in biotechnology and beyond.
AMES, Iowa, Jan. 27, 2025 /PRNewswire-PRWeb/ -- Zymosense, a pioneering nanotechnology firm and the leader in mobile "mix and read" enzyme activity assays, today announced the appointment of three accomplished leaders on its executive team. Nigel Reuel, Ph.D., has been named Chairman of the Board; Scott D. Nelson will serve as Chief Executive Officer; and Nathaniel Kallmyer, Ph.D., has been appointed Chief Technology Officer.
These strategic appointments underscore Zymosense's commitment to nanotechnology by advancing enzyme measurement and driving innovation in agriculture, biofuels, food processing and pharmaceuticals.
Dr. Nigel Reuel, Founder, has been appointed Chairman of the Board. Dr. Reuel brings a wealth of experience in bioengineering and technology development. As a renowned academic and entrepreneur, Dr. Reuel has a proven track record of translating cutting-edge research into commercially successful technologies. His leadership will continue to guide Zymosense in strengthening its market position and expanding its global reach.
"I am honored to continue to chair Zymosense at such a transformative moment," said Dr. Reuel. "The company's unique mobile enzyme assay technology holds tremendous potential to revolutionize how industries measure enzyme activity, and I look forward to supporting the team as we bring this innovation to the forefront."
As Chief Executive Officer, Scott D. Nelson will oversee Zymosense's operational excellence and strategic growth initiatives. With decades of executive leadership experience in scaling technology companies, Mr. Nelson has a reputation for optimizing processes and delivering sustained growth.
Nathaniel Kallmyer, Ph.D., Founder, has been appointed to Chief Technology Officer. Dr. Kallmyer will spearhead the company's R&D and product development efforts. Dr. Kallmyer's extensive expertise in nanotechnology and assay development positions him perfectly to lead Zymosense's technological advancements, ensuring the company stays ahead of industry trends and continues to deliver cutting-edge solutions.
"This is an exciting time for Zymosense and this industry," said CEO Scott D. Nelson, "I am privileged to lead the people of Zymosense to innovate, scale and serve our customers with segment leading solutions. Together, we are poised to transform the way nanotechnology is used to measure enzyme activity around the world."
Zymosense's flagship mobile "mix and read" assay technology is the first of its kind, enabling rapid and precise enzyme activity measurements on-site and in near real-time without the need for complex lab equipment. This breakthrough technology is being adopted across various industries, including pharmaceuticals, agriculture, and food production, to enhance efficiency and accuracy in enzyme analysis. It also can be used in high throughput screening campaigns providing the critical sequence to function data needed to train machine learning guided design or proteins. For more information about Zymosense and its leadership team, visit https://www.zymosense.com
Media Contact:
Scott D. Nelson
[email protected]
Media Contact
Scott D Nelson, Zymosense, 1 303-887-5476, [email protected], https://www.zymosense.com
SOURCE Zymosense
Share this article